SLDB Q1 2023 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$644M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$32M

Net Income

-$30M

EPS (Diluted)

$-1.54

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$29M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$230M

Total Liabilities

$46M

Stockholders' Equity

$184M

Cash & Equivalents

$165M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$2M	-100.0%
Gross Profit	$0	$2M	-100.0%
Operating Income	-$32M	-$25M	-26.2%
Net Income	-$30M	-$25M	-18.7%